Acadia Pharma (NASDAQ: ACAD) reported Q1 EPS of ($0.40), $0.13 worse than the analyst estimate of ($0.27). Revenue for the quarter came in at $4 thousand versus the consensus estimate of $80 thousand.

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.